Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib

This article was originally published in Scrip

Executive Summary

Galapagos NV, which suffered a major shock in September when AbbVie decided not to exercise its option on their JAK1 inhibitor filgotinib, has secured $725m up front from Gilead Sciences Inc. for the promising rheumatoid arthritis treatment.

Advertisement

Related Content

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen
Ablynx Builds Case For AbbVie Option On Humira Successor

Topics

Advertisement
UsernamePublicRestriction

Register

SC064018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel